Search Within

Dmitriy Zamarin

  1. "Cancer Research"
Formats
  1. Meeting Abstract (11)
  2. Editorial (1)
  3. Journal Article (1)
Groups
  1. Department of Medicine (13)
  2. GDMT, Medicine (13)
  3. Gynecologic Medicine Service (13)
  4. Gynecology Disease Management Team (13)
  5. Solid Tumor Oncology Division (13)
  6. Graduate Medical Education (5)

More Groups

People
  1. Claire Friedman (3)
  2. Andrew Mcpherson (2)
  3. Britta Weigelt (2)
  4. Carol Aghajanian (2)
  5. Kathryn Miller (2)
  6. Nicholas Ceglia (2)

More People

Years
  1. 2022 (10)
  2. 2020 (2)
  3. 2018 (1)
Publications
  1. Cancer Research (13)
Publishers
  1. American Association for Cancer Research (13)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)
    Meeting Abstract

    Spigel, D.; Spira, A.; Zamarin, D.; McDermott, D. F.; Luke, J.; Heymach, J. V.; Previs, R.; Sullivan, R.; Gandhi, L.; Azrilevich, A.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors
    Meeting Abstract

    Carneiro, B. A.; Zamarin, D.; Marron, T.; Mehmi, I.; Patel, S. P.; Subbiah, V.; El-Khoueiry, A.; Grand, D.; Garcia-Reyes, K.; Goel, S.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors
    Meeting Abstract

    Purroy, N.; Durham, N.; Phillips, M.; Hattersley, M. M.; Jung, L.; Davar, D.; Zamarin, D.; Johanns, T. M.; Puzanov, I.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade
    Meeting Abstract

    Muroyama, Y.; Manne, S.; Oldridge, D. A.; Wellhausen, N.; Greenplate, A. R.; Chilukuri, L.; Mathew, D.; Xu, C.; Herati, R. S.; Huang, A. C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Synthetic lethality by targeting ribonucleotide reductase in PP2A deficient uterine serous carcinoma
    Meeting Abstract

    O'Connor, C. M.; Taylor, S. E.; Miller, K. M.; Hurst, L.; Haanen, T. J.; Suhan, T. K.; Zawacki, K. P.; Noto, F. K.; Trako, J.; Mohan, A.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Defining the balance of anti-viral and anti-tumor T cell responses to oncolytic virus therapy using single cell approaches
    Meeting Abstract

    Burman, B.; Ceglia, N.; Hirschhorn, D.; Budhu, S.; Mangarin, L.; Oseledchyk, A.; Bykov, Y.; McPherson, A.; Shah, S.; Wolchok, J.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes
    Meeting Abstract

    Vázquez-García, I.; Uhlitz, F.; Ceglia, N.; Lim, J. L.; Wu, M.; Mohibullah, N.; Ruiz, A. E. B.; Boehm, K. M.; Bojilova, V.; Fong, C. J.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Endogenous retrotransposable elements induction in SMARCA4-deficient ovarian cancer is associated with immunomodulatory changes in the tumor microenvironment
    Meeting Abstract

    Brodeur, M. N.; Sun, S.; Zhu, Y.; Greenbaum, B.; Weigelt, B.; Zamarin, D.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Beyond T cells: IgA incites immune recognition in endometrial cancer
    Editorial

    Osorio, J. C.; Zamarin, D.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma
    Journal Article

    O'Connor, C. M.; Taylor, S. E.; Miller, K. M.; Hurst, L.; Haanen, T. J.; Suhan, T. K.; Zawacki, K. P.; Noto, F. K.; Trako, J.; Mohan, A.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save